© 2001 by Oxford University Press
Journal of the National Cancer Institute, Vol. 93, No. 16, 1190-1191,
August 15, 2001
© 2001 Oxford University Press
EDITORIAL |
Molecular Targeting: the New Challenge in Lung Cancer Prevention
Correspondence to: Ugo Pastorino, M.D., Division of Thoracic Surgery, Istituto Europeo di Oncologia, Via Ripamonti 435, 20141, Milan, Italy (e-mail: ugo.pastorino@ieo.it).
Negative results from large-scale clinical trials (13) have resulted in a general skepticism toward lung cancer chemoprevention in humans. One has to consider, however, the enormous difficulties that clinicians encountered in their early attempts to counteract lung carcinogenesis, including attempts at intervention in individuals with decades of intense smoking exposure, or even during active smoking, using single chemopreventive agents that had limited proven efficacy and substantial side effects.
From this first generation of clinical trials, we have learned that retinoids may be active only at relatively high doses, where toxicity becomes a limiting
REFERENCES